Get the Stockscreener App
9.64
3.50%
-0.35
Syndax Pharmaceuticals Inc stock is traded at $9.64, with a volume of 1.81M.
It is down -3.50% in the last 24 hours and up +6.52% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$9.99
Open:
$9.94
24h Volume:
1.81M
Relative Volume:
0.86
Market Cap:
$967.17M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.2568
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-14.23%
1M Performance:
+6.52%
6M Performance:
-29.27%
1Y Performance:
-51.51%
1-Day Range:
$9.595
$10.10
1-Week Range:
$9.595
$11.38
52-Week Range:
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
9.64 | 967.17M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Learn to Evaluate (SNDX) using the Charts - news.stocktradersdaily.com
Syndax Pharmaceuticals’ SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%What's Next? - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax reports publication of revumenib data from BEAT AML trial - Yahoo Finance
SNDX Trial Data Shows Promising Results in AML Treatment | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in - GlobeNewswire
Syndax Announces Publication of Revumenib Data from the BEAT AML - GuruFocus
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Announces Publication of Revumenib Data from the - GlobeNewswire
Clinical Trial: New AML Drug Achieves 100% MRD Negativity, Doubles Survival vs Standard Care - Stock Titan
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of ... - Eagle-Tribune
Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj - The Pharma Letter
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refra - GuruFocus
SNDX: New Data Revealed from Syndax's AUGMENT-101 Trial | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - The Manila Times
Syndax Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Canada
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - MSN
Syndax Pharmaceuticals at Jefferies Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Li - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC - MarketBeat
Voloridge Investment Management LLC Acquires Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat
84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.91 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat
Syndax Announces Participation in June Investor Conferences | SN - GuruFocus
Syndax Announces Participation in June Investor Conferences - The Manila Times
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 5.7%Here's Why - MarketBeat
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):